Till sidinnehåll


Agarwal, A., Ranganathan, P., Kattal, N., Pasqualotto, F., Hallak, J., Khayal, S., & Mascha, E. (2004). Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril, 81(2), 342-348. https://doi.org/10.1016/j.fertnstert.2003.07.021

Altieri, A., Bermejo, J. L., & Hemminki, K. (2005). Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood, 106(2), 668-672. https://doi.org/10.1182/blood-2005-01-0140

Altmann, B., Wulf, G., Truemper, L., d'Amore, F., Relander, T., Toldbod, H., Delabie, J. M. A., Rosenwald, A., Ziepert, M., & Loeffler, M. (2018). Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials. Blood, 132(Supplement 1), 1622-1622. https://doi.org/10.1182/blood-2018-99-112076

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. https://doi.org/10.1182/blood-2016-03-643544

Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, L., & Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol, 7, 24. https://doi.org/10.1186/1756-8722-7-24

Bassan, R., Maino, E., & Cortelazzo, S. (2016). Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol, 96(5), 447-460. https://doi.org/10.1111/ejh.12722

Baudino, B., D'Agata, F., Caroppo, P., Castellano, G., Cauda, S., Manfredi, M., Geda, E., Castelli, L., Mortara, P., Orsi, L., Cauda, F., Sacco, K., Ardito, R. B., Pinessi, L., Geminiani, G., Torta, R., & Bisi, G. (2012). The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging, 56(6), 559-568.

Beitinjaneh, A., Saliba, R. M., Medeiros, L. J., Turturro, F., Rondon, G., Korbling, M., Fayad, L., Fanale, M. A., Alousi, A. M., Anderlini, P., Betul, O., Popat, U. R., Pro, B., & Khouri, I. F. (2015). Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant, 21(5), 855-859. https://doi.org/10.1016/j.bbmt.2015.01.013

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., Henderson, W. G., Maynard, C., Hawn, M. T., Tonnesen, H., Hughes, G., Beste, L. A., Harris, A. H., Hawkins, E. J., Houston, T. K., & Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. https://doi.org/10.1007/s11606-010-1475-x

Brusamolino, E., Rusconi, C., Montalbetti, L., Gargantini, L., Uziel, L., Pinotti, G., Fava, S., Rigacci, L., Pagnucco, G., Pascutto, C., Morra, E., & Lazzarino, M. (2006). Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica, 91(4), 496-502.

Cairo, M. S., Coiffier, B., Reiter, A., & Younes, A. (2010). Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol, 149(4), 578-586. https://doi.org/10.1111/j.1365-2141.2010.08143.x

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 32(27), 3059-3068. https://doi.org/10.1200/jco.2013.54.8800

Clemens, M. W., Medeiros, L. J., Butler, C. E., Hunt, K. K., Fanale, M. A., Horwitz, S., Weisenburger, D. D., Liu, J., Morgan, E. A., Kanagal-Shamanna, R., Parkash, V., Ning, J., Sohani, A. R., Ferry, J. A., Mehta-Shah, N., Dogan, A., Liu, H., Thormann, N., Di Napoli, A., Lade, S., Piccolini, J., Reyes, R., Williams, T., McCarthy, C. M., Hanson, S. E., Nastoupil, L. J., Gaur, R., Oki, Y., Young, K. H., & Miranda, R. N. (2016). Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol, 34(2), 160-168. https://doi.org/10.1200/jco.2015.63.3412

d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Osterborg, A., Merup, M., Brown, P., Kuittinen, O., Erlanson, M., Ostenstad, B., Fagerli, U. M., Gadeberg, O. V., Sundstrom, C., Delabie, J., Ralfkiaer, E., Vornanen, M., & Toldbod, H. E. (2012). Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol, 30(25), 3093-3099. https://doi.org/10.1200/jco.2011.40.2719

Damaj, G., Gressin, R., Bouabdallah, K., Cartron, G., Choufi, B., Gyan, E., Banos, A., Jaccard, A., Park, S., Tournilhac, O., Schiano-de Collela, J. M., Voillat, L., Joly, B., Le Gouill, S., Saad, A., Cony-Makhoul, P., Vilque, J. P., Sanhes, L., Schmidt-Tanguy, A., Bubenheim, M., Houot, R., Diouf, M., Marolleau, J. P., Bene, M. C., Martin, A., & Lamy, T. (2013). Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol, 31(1), 104-110. https://doi.org/10.1200/jco.2012.43.7285

Dearden, C. (2015). Management of prolymphocytic leukemia. Hematology Am Soc Hematol Educ Program, 2015, 361-367. https://doi.org/10.1182/asheducation-2015.1.361

Dearden, C. E., Khot, A., Else, M., Hamblin, M., Grand, E., Roy, A., Hewamana, S., Matutes, E., & Catovsky, D. (2011). Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood, 118(22), 5799-5802. https://doi.org/10.1182/blood-2011-08-372854

Del Mastro, L., Ceppi, M., Poggio, F., Bighin, C., Peccatori, F., Demeestere, I., Levaggi, A., Giraudi, S., Lambertini, M., D'Alonzo, A., Canavese, G., Pronzato, P., & Bruzzi, P. (2014). Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev, 40(5), 675-683. https://doi.org/10.1016/j.ctrv.2013.12.001

Delabie, J., Holte, H., Vose, J. M., Ullrich, F., Jaffe, E. S., Savage, K. J., Connors, J. M., Rimsza, L., Harris, N. L., Muller-Hermelink, K., Rudiger, T., Coiffier, B., Gascoyne, R. D., Berger, F., Tobinai, K., Au, W. Y., Liang, R., Montserrat, E., Hochberg, E. P., Pileri, S., Federico, M., Nathwani, B., Armitage, J. O., & Weisenburger, D. D. (2011). Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood, 118(1), 148-155. https://doi.org/10.1182/blood-2011-02-335216

Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., Gennery, A. R., Kuball, J., Lankester, A. C., Lanza, F., Montoto, S., Nagler, A., Peffault de Latour, R., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Kröger, N., & Mohty, M. (2019). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant, 54(10), 1525-1552. https://doi.org/10.1038/s41409-019-0516-2

Ekberg, S., K, E. S., Glimelius, I., Nilsson-Ehle, H., Goldkuhl, C., Lewerin, C., Jerkeman, M., & Eloranta, S. (2020). Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study. Br J Haematol. https://doi.org/10.1111/bjh.16489

Ellin, F., Landstrom, J., Jerkeman, M., & Relander, T. (2014). Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood, 124(10), 1570-1577. https://doi.org/10.1182/blood-2014-04-573089

Ellin, F., Landstrom, J., Jerkeman, M., & Relander, T. (2015). Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood, 126(1), 36-41. https://doi.org/10.1182/blood-2014-12-616961

Ellin, F., Maurer, M. J., Srour, L., Farooq, U., Jerkeman, M., Connors, J. M., Smedby, K. E., Bennani, N. N., Ansell, S. M., Slack, G. W., Cerhan, J. R., Relander, T., Feldman, A. L., & Savage, K. J. (2019). Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol, 186(3), e24-e27. https://doi.org/10.1111/bjh.15859

Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A. P., Repp, R., Schetelig, J., Seipelt, G., & Osterborg, A. (2004). A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103(8), 2920-2924. https://doi.org/10.1182/blood-2003-10-3389

Fallon, M. J., & Heck, J. N. (2015). Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract, 21(5), 388-392. https://doi.org/10.1177/1078155214533368

Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquieres, H., Tournilhac, O., da Silva, M. G., Bouabdallah, R., Salles, G., & Bachy, E. (2018). Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol, 29(3), 715-723. https://doi.org/10.1093/annonc/mdx787

Gascoyne, R. D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B. F., Greiner, T. C., Morris, S. W., Connors, J. M., Vose, J. M., Viswanatha, D. S., Coldman, A., & Weisenburger, D. D. (1999). Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93(11), 3913-3921.

Gazitt, T., & Loughran, T. P., Jr. (2017). Chronic neutropenia in LGL leukemia and rheumatoid arthritis. Hematology Am Soc Hematol Educ Program, 2017(1), 181-186. https://doi.org/10.1182/asheducation-2017.1.181

Geller, S., Myskowski, P. L., Pulitzer, M., Horwitz, S. M., & Moskowitz, A. J. (2019). Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chin Clin Oncol, 8(1), 5. https://doi.org/10.21037/cco.2018.11.01

Goldin, L. R., Bjorkholm, M., Kristinsson, S. Y., Turesson, I., & Landgren, O. (2009). Highly increased familial risks for specific lymphoma subtypes. Br J Haematol, 146(1), 91-94. https://doi.org/10.1111/j.1365-2141.2009.07721.x

Hari, P., Raj, R. V., & Olteanu, H. (2016). Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. N Engl J Med, 375(15), 1501-1502. https://doi.org/10.1056/NEJMc1605684

Hellbom, M., & Thomé, B. (2011). Perspektiv på onkologisk vård. Studentlitteratur.

Hermine, O., Bouscary, D., Gessain, A., Turlure, P., Leblond, V., Franck, N., Buzyn-Veil, A., Rio, B., Macintyre, E., Dreyfus, F., & et al. (1995). Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med, 332(26), 1749-1751. https://doi.org/10.1056/nejm199506293322604

Hermine, O., Ramos, J. C., & Tobinai, K. (2018). A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. Adv Ther, 35(2), 135-152. https://doi.org/10.1007/s12325-018-0658-4

Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illes, A., Tobinai, K., Tsukasaki, K., Yeh, S. P., Shustov, A., Huttmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., & Trumper, L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 393(10168), 229-240. https://doi.org/10.1016/s0140-6736(18)32984-2

Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood, 123(20), 3095-3100. https://doi.org/10.1182/blood-2013-12-542142

Hovatta, O. (2004). Cryopreservation and culture of human ovarian cortical tissue containing early follicles. Eur J Obstet Gynecol Reprod Biol, 113 Suppl 1, S50-54. https://doi.org/10.1016/j.ejogrb.2003.11.012

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., Kawakami, Y., Matsui, Y., Tsujii, H., Mizoe, J., Oda, E., Fukunaga, Y., & Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307. http://www.ncbi.nlm.nih.gov/pubmed/16929125

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. https://doi.org/10.1002/cncr.22452

Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R. J., Weber, W. A., Reske, S. N., Schwaiger, M., Schwartz, L. H., Zijlstra, J. M., Siegel, B. A., & Cheson, B. D. (2007). Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25(5), 571-578. https://doi.org/10.1200/jco.2006.08.2305

Kato, K., & Akashi, K. (2015). Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma. Viruses, 7(12), 6604-6612. https://doi.org/10.3390/v7122960

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. https://doi.org/10.1200/JCO.2007.13.3033

Kheterpal, M., Mehta-Shah, N., Virmani, P., Myskowski, P. L., Moskowitz, A., & Horwitz, S. M. (2016). Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Curr Hematol Malig Rep, 11(3), 224-233. https://doi.org/10.1007/s11899-016-0322-5

Kim, H., Jeong, H., Yamaguchi, M., Sohn, I., Yoon, S. E., Byeon, S., Hur, J. Y., Koh, Y., Yoon, S. S., Kim, E. J., Oguchi, M., Miyazaki, K., Taguchi, S., Yoon, D. H., Cho, J., Ko, Y. H., Kim, S. J., Suzuki, R., & Kim, W. S. (2020). Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood, 136(22), 2548-2556. https://doi.org/10.1182/blood.2020005026

Kim, H. S., Kim, K. H., Kim, K. H., Chang, M. H., Ji, S. H., Lim, D. H., Kim, K., Kim, S. J., Ko, Y., Ki, C. S., Jo, S. J., Lee, J. W., & Kim, W. S. (2009). Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma, 50(5), 757-763. https://doi.org/10.1080/10428190902803669

Kim, S. J., Kim, K., Kim, B. S., Kim, C. Y., Suh, C., Huh, J., Lee, S. W., Kim, J. S., Cho, J., Lee, G. W., Kang, K. M., Eom, H. S., Pyo, H. R., Ahn, Y. C., Ko, Y. H., & Kim, W. S. (2009). Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol, 27(35), 6027-6032. https://doi.org/10.1200/jco.2009.23.8592

Kim, S. J., Park, S., Kang, E. S., Choi, J. Y., Lim, D. H., Ko, Y. H., & Kim, W. S. (2015). Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol, 94(1), 71-78. https://doi.org/10.1007/s00277-014-2171-4

Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., Park, Y., Chang, K. M., Maeda, Y., Ishida, F., Shin, D. Y., Kim, J. S., Jeong, S. H., Yang, D. H., Jo, J. C., Lee, G. W., Choi, C. W., Lee, W. S., Chen, T. Y., Kim, K., Jung, S. H., Murayama, T., Oki, Y., Advani, R., d'Amore, F., Schmitz, N., Suh, C., Suzuki, R., Kwong, Y. L., Lin, T. Y., & Kim, W. S. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol, 17(3), 389-400. https://doi.org/10.1016/s1470-2045(15)00533-1

Kim, S. S., Donnez, J., Barri, P., Pellicer, A., Patrizio, P., Rosenwaks, Z., Nagy, P., Falcone, T., Andersen, C., Hovatta, O., Wallace, H., Meirow, D., Gook, D., Kim, S. H., Tzeng, C. R., Suzuki, S., Ishizuka, B., & Dolmans, M. M. (2012). Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet, 29(6), 465-468. https://doi.org/10.1007/s10815-012-9786-y

Kotlyar, D. S., Osterman, M. T., Diamond, R. H., Porter, D., Blonski, W. C., Wasik, M., Sampat, S., Mendizabal, M., Lin, M. V., & Lichtenstein, G. R. (2011). A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 9(1), 36-41.e31. https://doi.org/10.1016/j.cgh.2010.09.016

Krolak, D., Collins, B., Weiss, L., Harris, C., & Van der Jagt, R. (2017). Cognitive function and its relationship to other psychosocial factors in lymphoma survivors. Support Care Cancer, 25(3), 905-913. https://doi.org/10.1007/s00520-016-3480-z

Kwong, Y. L., Chan, T. S. Y., Tan, D., Kim, S. J., Poon, L. M., Mow, B., Khong, P. L., Loong, F., Au-Yeung, R., Iqbal, J., Phipps, C., & Tse, E. (2017). PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood, 129(17), 2437-2442. https://doi.org/10.1182/blood-2016-12-756841

Lamarque, M., Bossard, C., Contejean, A., Brice, P., Parrens, M., Le Gouill, S., Briere, J., Bouabdallah, R., Canioni, D., Tilly, H., Bouchindhomme, B., Bachy, E., Delarue, R., Haioun, C., & Gaulard, P. (2016). Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica, 101(3), e103-106. https://doi.org/10.3324/haematol.2015.135400

Lepretre, S., Touzart, A., Vermeulin, T., Picquenot, J. M., Tanguy-Schmidt, A., Salles, G., Lamy, T., Bene, M. C., Raffoux, E., Huguet, F., Chevallier, P., Bologna, S., Bouabdallah, R., Benichou, J., Briere, J., Moreau, A., Tallon-Simon, V., Seris, S., Graux, C., Asnafi, V., Ifrah, N., Macintyre, E., & Dombret, H. (2016). Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol, 34(6), 572-580. https://doi.org/10.1200/jco.2015.61.5385

Levine, J. E., Harris, R. E., Loberiza, F. R., Jr., Armitage, J. O., Vose, J. M., Van Besien, K., Lazarus, H. M., Horowitz, M. M., Bashey, A., Bolwell, B. J., Burns, L. J., Cairo, M. S., Champlin, R. E., Freytes, C. O., Gibson, J., Goldstein, S. C., Laughlin, M. J., Lister, J., Marks, D. I., Maziarz, R. T., Miller, A. M., Milone, G. A., Pavlovsky, S., Pecora, A. L., Rizzo, J. D., Schiller, G., Schouten, H. C., & Zhang, M. J. (2003). A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood, 101(7), 2476-2482. https://doi.org/10.1182/blood-2002-05-1483

Li, X., Cui, Y., Sun, Z., Zhang, L., Li, L., Wang, X., Wu, J., Fu, X., Ma, W., Zhang, X., Chang, Y., Nan, F., Li, W., Su, L., Wang, J., Xue, H., & Zhang, M. (2016). DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-16-0153

Liu, L., He, X., & Feng, L. (2019). Exercise on quality of life and cancer-related fatigue for lymphoma survivors: a systematic review and meta-analysis. Support Care Cancer, 27(11), 4069-4082. https://doi.org/10.1007/s00520-019-04983-y

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. https://doi.org/10.1016/j.radonc.2004.09.002

Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L. H., Villa, D., Gascoyne, R. D., Connors, J. M., & Savage, K. J. (2013). Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol, 31(16), 1970-1976. https://doi.org/10.1200/jco.2012.44.7524

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter 102.

Marky, I., Bjork, O., Forestier, E., Jonsson, O. G., Perkkio, M., Schmiegelow, K., Storm-Mathiesen, I., & Gustafsson, G. (2004). Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology. J Pediatr Hematol Oncol, 26(9), 555-560.

Michonneau, D., Petrella, T., Ortonne, N., Ingen-Housz-Oro, S., Franck, N., Barete, S., Battistella, M., Beylot-Barry, M., Vergier, B., Maynadie, M., Bodemer, C., Hermine, O., Bagot, M., Brousse, N., & Fraitag, S. (2017). Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy. Acta Derm Venereol, 97(3), 358-364. https://doi.org/10.2340/00015555-2543

Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E., & Fisher, R. I. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med, 339(1), 21-26. https://doi.org/10.1056/nejm199807023390104

Murphy, F., Kroll, M. E., Pirie, K., Reeves, G., Green, J., & Beral, V. (2013). Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer, 108(11), 2390-2398. https://doi.org/10.1038/bjc.2013.159

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. https://doi.org/10.1007/s11605-010-1350-4

Nijeboer, P., de Baaij, L. R., Visser, O., Witte, B. I., Cillessen, S. A., Mulder, C. J., & Bouma, G. (2015). Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. Am J Hematol, 90(6), 493-498. https://doi.org/10.1002/ajh.23992

Nijeboer, P., Malamut, G., Mulder, C. J., Cerf-Bensussan, N., Sibon, D., Bouma, G., Cellier, C., Hermine, O., & Visser, O. (2015). Enteropathy-associated T-cell lymphoma: improving treatment strategies. Dig Dis, 33(2), 231-235. https://doi.org/10.1159/000369542

O'Connor, O. A., Lue, J. K., Sawas, A., Amengual, J. E., Deng, C., Kalac, M., Falchi, L., Marchi, E., Turenne, I., Lichtenstein, R., Rojas, C., Francescone, M., Schwartz, L., Cheng, B., Savage, K. J., Villa, D., Crump, M., Prica, A., Kukreti, V., Cremers, S., Connors, J. M., & Kuruvilla, J. (2018). Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol, 19(2), 257-266. https://doi.org/10.1016/s1470-2045(17)30912-9

Oshimi, K. (2017). Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. Intern Med, 56(14), 1759-1769. https://doi.org/10.2169/internalmedicine.56.8881

Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Advani, R. H., Feldman, T., Lechowicz, M. J., Smith, S. M., Lansigan, F., Tulpule, A., Craig, M. D., Greer, J. P., Kahl, B. S., Leach, J. W., Morganstein, N., Casulo, C., & Shustov, A. R. (2019). The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 125(9), 1507-1517. https://doi.org/10.1002/cncr.31861

Perry, A. M., Diebold, J., Nathwani, B. N., MacLennan, K. A., Muller-Hermelink, H. K., Bast, M., Boilesen, E., Armitage, J. O., & Weisenburger, D. D. (2016). Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project. Ann Hematol, 95(2), 245-251. https://doi.org/10.1007/s00277-015-2543-4

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Fenton, K., Huebner, D., Pinelli, J. M., Kennedy, D. A., & Shustov, A. (2017). Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 130(25), 2709-2717. https://doi.org/10.1182/blood-2017-05-780049

Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandern, R., Fanale, M. A., Connors,  J. M., Wang, Y., Huebner, D., Kennedy, D. A., Shustov, A. R. . (2014). Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (Blood 2014 124:3095; ed., Vol. 124). Blood.

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525. http://www.ncbi.nlm.nih.gov/pubmed/12110499

Qi, F., Chen, B., Wang, J., Lin, X., Qi, S., Yang, J., Zhou, S., Wang, S., Gui, L., Fang, H., Liu, P., Song, Y., Yang, S., Li, Y., & Dong, M. (2019). Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era. Leuk Lymphoma, 60(11), 2679-2688. https://doi.org/10.1080/10428194.2019.1599111

Rasmusson, E. M., Plantin, L., & Elmerstig, E. (2013). 'Did they think I would understand all that on my own?' A questionnaire study about sexuality with Swedish cancer patients. Eur J Cancer Care (Engl), 22(3), 361-369. https://doi.org/10.1111/ecc.12039

Reimer, P., Rudiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Muller-Hermelink, H. K., & Wilhelm, M. (2009). Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol, 27(1), 106-113. https://doi.org/10.1200/jco.2008.17.4870

Salama, M., Anazodo, A., & Woodruff, T. K. (2019). Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol, 30(11), 1760-1775. https://doi.org/10.1093/annonc/mdz284

Sanikommu, S. R., Clemente, M. J., Chomczynski, P., Afable, M. G., 2nd, Jerez, A., Thota, S., Patel, B., Hirsch, C., Nazha, A., Desamito, J., Lichtin, A., Pohlman, B., Sekeres, M. A., Radivoyevitch, T., & Maciejewski, J. P. (2018). Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma, 59(2), 416-422. https://doi.org/10.1080/10428194.2017.1339880

Savage, K. J., Chhanabhai, M., Gascoyne, R. D., & Connors, J. M. (2004). Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol, 15(10), 1467-1475. https://doi.org/10.1093/annonc/mdh392

Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., Armitage, J. O., & Weisenburger, D. D. (2008). ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 111(12), 5496-5504. https://doi.org/10.1182/blood-2008-01-134270

Schmitz, N., Trumper, L., Ziepert, M., Nickelsen, M., Ho, A. D., Metzner, B., Peter, N., Loeffler, M., Rosenwald, A., & Pfreundschuh, M. (2010). Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 116(18), 3418-3425. https://doi.org/10.1182/blood-2010-02-270785

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. https://doi.org/10.1016/j.breast.2013.07.047

Sibon, D., Fournier, M., Briere, J., Lamant, L., Haioun, C., Coiffier, B., Bologna, S., Morel, P., Gabarre, J., Hermine, O., Sonet, A., Gisselbrecht, C., Delsol, G., Gaulard, P., & Tilly, H. (2012). Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol, 30(32), 3939-3946. https://doi.org/10.1200/jco.2012.42.2345

Sieniawski, M., Angamuthu, N., Boyd, K., Chasty, R., Davies, J., Forsyth, P., Jack, F., Lyons, S., Mounter, P., Revell, P., Proctor, S. J., & Lennard, A. L. (2010). Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood, 115(18), 3664-3670. https://doi.org/10.1182/blood-2009-07-231324

Sjövall, K. (2011). Patienters perspektiv och upplevelser av cancersjukdom och cancervård. In H. M. Thomé B. (Ed.), Perspektiv på onkologisk vård (pp. 131-148). Studentlitteratur.

[Record #18 is using a reference type undefined in this output style.]

Staber, P. B., Herling, M., Bellido, M., Jacobsen, E. D., Davids, M. S., Kadia, T. M., Shustov, A., Tournilhac, O., Bachy, E., Zaja, F., Porkka, K., Hoermann, G., Simonitsch-Klupp, I., Haferlach, C., Kubicek, S., Mayerhoefer, M. E., Hopfinger, G., Jaeger, U., & Dearden, C. (2019). Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 134(14), 1132-1143. https://doi.org/10.1182/blood.2019000402

Steinway, S. N., LeBlanc, F., & Loughran, T. P., Jr. (2014). The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev, 28(3), 87-94. https://doi.org/10.1016/j.blre.2014.02.001

Sweetenham, J. W., Santini, G., Qian, W., Guelfi, M., Schmitz, N., Simnett, S., Nagler, A., Holte, H., Kvaloy, S., Bruzzi, P., & Goldstone, A. H. (2001). High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol, 19(11), 2927-2936.

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., & Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375-2390. https://doi.org/10.1182/blood-2016-01-643569

Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T., & Nagai, H. (2009). Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol, 27(11), 1906-1914. https://doi.org/10.1200/jco.2008.16.0861

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. https://doi.org/10.1093/bja/aen401

Walker, J. N., Hanson, B. M., Pinkner, C. L., Simar, S. R., Pinkner, J. S., Parikh, R., Clemens, M. W., Hultgren, S. J., & Myckatyn, T. M. (2019). Insights into the Microbiome of Breast Implants and Periprosthetic Tissue in Breast Implant-Associated Anaplastic Large Cell Lymphoma. Sci Rep, 9(1), 10393. https://doi.org/10.1038/s41598-019-46535-8

van Casteren, N. J., van Santbrink, E. J., van Inzen, W., Romijn, J. C., & Dohle, G. R. (2008). Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil Steril, 90(6), 2245-2250. https://doi.org/10.1016/j.fertnstert.2007.10.055

van de Water, J. M., Nijeboer, P., de Baaij, L. R., Zegers, J., Bouma, G., Visser, O. J., van der Peet, D. L., Mulder, C. J., & Meijerink, W. J. (2015). Surgery in (pre)malignant celiac disease. World J Gastroenterol, 21(43), 12403-12409. https://doi.org/10.3748/wjg.v21.i43.12403

Wang, L., Wang, Z. H., Chen, X. Q., Li, Y. J., Wang, K. F., Xia, Y. F., & Xia, Z. J. (2013). First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer, 119(2), 348-355. https://doi.org/10.1002/cncr.27752

Wang, S. S., Flowers, C. R., Kadin, M. E., Chang, E. T., Hughes, A. M., Ansell, S. M., Feldman, A. L., Lightfoot, T., Boffetta, P., Melbye, M., Lan, Q., Sampson, J. N., Morton, L. M., Zhang, Y., & Weisenburger, D. D. (2014). Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014(48), 66-75. https://doi.org/10.1093/jncimonographs/lgu012

Wei, W., Wu, P., Li, L., & Zhang, Z. H. (2017). Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology, 22(6), 320-329. https://doi.org/10.1080/10245332.2016.1264163

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., MacDougall, H., Samuel, L., & Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. https://doi.org/10.1016/j.radonc.2004.07.032

Vermaete, N., Wolter, P., Verhoef, G., & Gosselink, R. (2013). Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol, 92(8), 1007-1021. https://doi.org/10.1007/s00277-013-1689-1

Vermaete, N., Wolter, P., Verhoef, G., & Gosselink, R. (2014). Physical activity and physical fitness in lymphoma patients before, during, and after chemotherapy: a prospective longitudinal study. Ann Hematol, 93(3), 411-424. https://doi.org/10.1007/s00277-013-1881-3

Vose, J., Armitage, J., & Weisenburger, D. (2008). International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol, 26(25), 4124-4130. https://doi.org/10.1200/jco.2008.16.4558

Yabe, M., Miranda, R. N., & Medeiros, L. J. (2018). Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol, 74, 5-16. https://doi.org/10.1016/j.humpath.2018.01.005

Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y. X., Tsang, R., & Wirth, A. (2015). Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys, 92(1), 11-31. https://doi.org/10.1016/j.ijrobp.2015.01.009

Yamaguchi, M., Kita, K., Miwa, H., Nishii, K., Oka, K., Ohno, T., Shirakawa, S., & Fukumoto, M. (1995). Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer, 76(11), 2351-2356. https://doi.org/10.1002/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1

Yang, L., Liu, H., Xu, X. H., Wang, X. F., Huang, H. M., Shi, W. Y., & Jiang, S. H. (2013). Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol, 30(4), 720. https://doi.org/10.1007/s12032-013-0720-7

Zheng, Y., Yang, C., Liang, T., Yang, D., & Liu, Z. (2020). Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type. Hematol Oncol, 38(1), 103-105. https://doi.org/10.1002/hon.2637

Zinzani, P. L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S., & Baccarani, M. (2010). Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol, 21(4), 860-863. https://doi.org/10.1093/annonc/mdp508